07:30 AM EDT, 08/30/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Friday that detailed results of its phase 3 study of vutrisiran showed a "non-significant" 30% reduction in the relative risk of death up to three years in the study's monotherapy group.

Vutrisiran is an investigational therapy for treating ATTR amyloidosis with cardiomyopathy, a heart disease.

Shares of Alnylam Pharmaceuticals ( ALNY ) were down more than 11% premarket Friday.

Apart from the monotherapy group, the study enrolled patients receiving concurrent treatment with standard-of-care therapies such as tafamidis and SGLT2 inhibitors.

In the study, treatment with vutrisiran "substantially" reduced the risk of death and cardiovascular events relative to placebo. In the overall population, the drug candidate reduced the risk of all-cause mortality and recurrent cardiovascular events by 28%, the company said.

The drug candidate also demonstrated an "encouraging" safety and tolerability profile consistent with the established profile of the drug.

As previously reported, the company said the study has achieved all 10 of its primary and secondary endpoints in both patient populations.

The company also said it remains on track for the drug candidate's global regulatory submissions later this year.

Price: 253.00, Change: -34.01, Percent Change: -11.85